Mayne Cements Place On US Generics Map

Asset divestments continue in the lead up to Teva's acquisition of Allergan's generics business.

Mayne Pharma Group Ltd. of Australia has agreed to buy a portfolio of US generic products from Teva Pharmaceutical Industries Ltd. and Allergan PLC for $652m. The portfolio consists of 37 approved products and 5 FDA-filed products in a range of territories and indications.

The two larger companies are making a series of divestments to gain antitrust approval for Teva's acquisition of Allergan's generics...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip